398 related articles for article (PubMed ID: 34540900)
1. The Functions of BET Proteins in Gene Transcription of Biology and Diseases.
Cheung KL; Kim C; Zhou MM
Front Mol Biosci; 2021; 8():728777. PubMed ID: 34540900
[TBL] [Abstract][Full Text] [Related]
2. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
Taniguchi Y
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
[TBL] [Abstract][Full Text] [Related]
3. Comparative structure-function analysis of bromodomain and extraterminal motif (BET) proteins in a gene-complementation system.
Werner MT; Wang H; Hamagami N; Hsu SC; Yano JA; Stonestrom AJ; Behera V; Zong Y; Mackay JP; Blobel GA
J Biol Chem; 2020 Feb; 295(7):1898-1914. PubMed ID: 31792058
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity.
Sartor GC; Powell SK; Brothers SP; Wahlestedt C
J Neurosci; 2015 Nov; 35(45):15062-72. PubMed ID: 26558777
[TBL] [Abstract][Full Text] [Related]
6. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
To KKW; Xing E; Larue RC; Li PK
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806
[TBL] [Abstract][Full Text] [Related]
7. The BRD3 ET domain recognizes a short peptide motif through a mechanism that is conserved across chromatin remodelers and transcriptional regulators.
Wai DCC; Szyszka TN; Campbell AE; Kwong C; Wilkinson-White LE; Silva APG; Low JKK; Kwan AH; Gamsjaeger R; Chalmers JD; Patrick WM; Lu B; Vakoc CR; Blobel GA; Mackay JP
J Biol Chem; 2018 May; 293(19):7160-7175. PubMed ID: 29567837
[TBL] [Abstract][Full Text] [Related]
8. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
[TBL] [Abstract][Full Text] [Related]
10. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
11. Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases.
Morgado-Pascual JL; Rayego-Mateos S; Tejedor L; Suarez-Alvarez B; Ruiz-Ortega M
Front Pharmacol; 2019; 10():1315. PubMed ID: 31780938
[TBL] [Abstract][Full Text] [Related]
12. Small-Molecule Targeting of BET Proteins in Cancer.
French CA
Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
[TBL] [Abstract][Full Text] [Related]
14. Bromodomain inhibitors and therapeutic applications.
Gajjela BK; Zhou MM
Curr Opin Chem Biol; 2023 Aug; 75():102323. PubMed ID: 37207401
[TBL] [Abstract][Full Text] [Related]
15. The bromodomains of BET family proteins can recognize diacetylated histone H2A.Z.
Patel K; Solomon PD; Walshe JL; Low JKK; Mackay JP
Protein Sci; 2021 Feb; 30(2):464-476. PubMed ID: 33247496
[TBL] [Abstract][Full Text] [Related]
16. Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers.
Sun HY; Du ST; Li YY; Deng GT; Zeng FR
World J Gastrointest Oncol; 2022 Jan; 14(1):75-89. PubMed ID: 35116104
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Modulation of BET Family in Sepsis.
Wang N; Wu R; Comish PB; Kang R; Tang D
Front Pharmacol; 2021; 12():642294. PubMed ID: 33776776
[TBL] [Abstract][Full Text] [Related]
18. Targeting the epigenetic reader "BET" as a therapeutic strategy for cancer.
Wahi A; Manchanda N; Jain P; Jadhav HR
Bioorg Chem; 2023 Nov; 140():106833. PubMed ID: 37683545
[TBL] [Abstract][Full Text] [Related]
19. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
[TBL] [Abstract][Full Text] [Related]
20. RNAs interact with BRD4 to promote enhanced chromatin engagement and transcription activation.
Rahnamoun H; Lee J; Sun Z; Lu H; Ramsey KM; Komives EA; Lauberth SM
Nat Struct Mol Biol; 2018 Aug; 25(8):687-697. PubMed ID: 30076409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
